六个高收入国家急性心肌梗死患者血运重建使用与结局的差异:横断面队列研究
该回顾性横断面队列研究利用美国、加拿大(安大略和马尼托巴)、英格兰、荷兰、以色列和台湾2011年1月1日至2017年12月31日66岁及以上STEMI或NSTEMI住院患者的行政数据,比较血运重建、死亡率和效率三类结局,并按2017年美国急性心肌梗死人群的年龄和性别分布标准化。结果显示各国所有结局均存在巨大差异,例如2017年STEMI住院PCI比例从英格兰36.9%到加拿大78.6%(美国71.8%),STEMI一年内死亡从荷兰18.9%到美国27.8%和台湾32.3%。结论认为各国均有表现优异的领域,但无一国在三个领域均表现卓越,提示可通过患者层面全国代表性数据的国际比较相互学习。
要点
- 2017年STEMI住院PCI比例:英格兰36.9%、加拿大78.6%、美国71.8%,各国2011至2017年均上升,以色列(48.4%升至65.9%)和台湾(49.4%升至70.2%)升幅尤大。
- 2017年NSTEMI入院90天内CABG比例:荷兰最低3.5%,美国最高11.7%。
- 2017年STEMI入院一年内死亡:荷兰18.9%、美国27.8%、台湾32.3%。
- 2017年STEMI平均住院日:荷兰5.0天、美国5.1天最低,台湾8.5天最高;30天再入院台湾11.7%、美国12.2%最低,英格兰23.1%最高。
- 六个高收入国家中无一国在血运重建、死亡率和效率三个领域均表现优异,各国均有表现优异的领域。
适用人群与场景
- 美国、加拿大(安大略和马尼托巴)、英格兰、荷兰、以色列和台湾2011年1月1日至2017年12月31日期间因STEMI或NSTEMI住院的66岁及以上成人。
研究设计与关键结果
- 研究类型为回顾性横断面队列研究,使用美国、加拿大(安大略和马尼托巴)、英格兰、荷兰、以色列和台湾的患者层面行政数据;总住院人次从以色列19 043例到美国1 064 099例。
- 2017年STEMI住院PCI比例从英格兰36.9%到加拿大78.6%(美国71.8%);2011至2017年所有国家STEMI的PCI使用均增加,以色列(48.4%升至65.9%)和台湾(49.4%升至70.2%)升幅尤大。
- 2017年NSTEMI入院90天内CABG比例荷兰最低(3.5%),美国最高(11.7%)。
- 2017年STEMI入院一年内死亡从荷兰18.9%到美国27.8%和台湾32.3%。
- 2017年STEMI平均住院日荷兰和美国最低(5.0天和5.1天),台湾最高(8.5天);STEMI 30天再入院台湾(11.7%)和美国(12.2%)最低,英格兰(23.1%)最高。
证据类型、等级与局限
- 证据类型:回顾性横断面队列研究,基于行政数据,按2017年美国急性心肌梗死人群的年龄和性别分布标准化。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,各国可通过患者层面全国代表性数据的国际比较相互学习。
- 原文未据此给出推荐。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
OBJECTIVES: To compare treatment and outcomes for patients admitted to hospital with a primary diagnosis of ST elevation or non-ST elevation myocardial infarction (STEMI or NSTEMI) in six high income countries with very different healthcare delivery systems.
DESIGN: Retrospective cross sectional cohort study.
SETTING: Patient level administrative data from the United States, Canada (Ontario and Manitoba), England, the Netherlands, Israel, and Taiwan.
PARTICIPANTS: Adults aged 66 years and older admitted to hospital with STEMI or NSTEMI between 1 January 2011 and 31 December 2017.
OUTCOMES MEASURES: The three categories of outcomes were coronary revascularisation (percutaneous coronary intervention or coronary artery bypass graft surgery), mortality, and efficiency (hospital length of stay and 30 day readmission). Rates were standardised to the age and sex distribution of the US acute myocardial infarction population in 2017. Outcomes were assessed separately for STEMI and NSTEMI. Performance was evaluated longitudinally (over time) and cross sectionally (between countries).
RESULTS: The total number of hospital admissions ranged from 19 043 in Israel to 1 064 099 in the US. Large differences were found between countries for all outcomes. For example, the proportion of patients admitted to hospital with STEMI who received percutaneous coronary intervention in hospital during 2017 ranged from 36.9% (England) to 78.6% (Canada; 71.8% in the US); use of percutaneous coronary intervention for STEMI increased in all countries between 2011 and 2017, with particularly large rises in Israel (48.4-65.9%) and Taiwan (49.4-70.2%). The proportion of patients with NSTEMI who underwent coronary artery bypass graft surgery within 90 days of admission during 2017 was lowest in the Netherlands (3.5%) and highest in the US (11.7%). Death within one year of admission for STEMI in 2017 ranged from 18.9% (Netherlands) to 27.8% (US) and 32.3% (Taiwan). Mean hospital length of stay in 2017 for STEMI was lowest in the Netherlands and the US (5.0 and 5.1 days) and highest in Taiwan (8.5 days); 30 day readmission for STEMI was lowest in Taiwan (11.7%) and the US (12.2%) and highest in England (23.1%).
CONCLUSIONS: In an analysis of myocardial infarction in six high income countries, all countries had areas of high performance, but no country excelled in all three domains. Our findings suggest that countries could learn from each other by using international comparisons of patient level nationally representative data.
参考来源
- Cram P, Hatfield LA, Bakx P, et al. Variation in revascularisation use and outcomes of patients in hospital with acute myocardial infarction across six high income countries: cross sectional cohort study. BMJ. 2022. PMID: 35508312. doi:10.1136/bmj-2021-069164
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。